Forward P/S Multiple: INVO Bioscience Inc. (INVO)
High equipment assembly costs create financial risks, as evidenced by the forward P/S history, where the ratio stands at 0.30. INVO Bioscience, Inc. (INVO) achieves cost optimization through contract manufacturing and external support. The current development vector is based on creating a digital network of reproduction clinics following a strategic merger, transforming the business model into a vertically integrated system.
Summary analytical data breakdowns for invobioscience.com (INVO)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital INVO Bioscience, Inc.|INVO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital INVO Bioscience|INVO - Company Aggregate Debts|Debt to Book Capitalization Ratio INVO Bioscience, Inc.|INVO - Company Long-Term Debt|Company Current Liabilities INVO Bioscience|Quick Ratio invobioscience.com
- financial results and valuation multiples details:
INVO - Company Net Income|Expected Profit INVO Bioscience, Inc.|INVO - Market Cap to Net Income Ratio|Projected Price to Earnings INVO Bioscience|INVO - PEG Multiple|EV/EBITDA Multiple INVO Bioscience, Inc.|INVO - Operating income before deduction of amortization|Earnings per share for the last twelve months INVO Bioscience|INVO - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months invobioscience.com|INVO - Net earnings per share growth this year|Earnings growth forecast for next year INVO Bioscience, Inc.
- sales and revenue indicators:
Fundamental company analysis:INVO (INVO Bio)
Investors utilize forward multiples to verify an asset's market value relative to its future cash flows. The ratio of current price to expected revenue, illustrated by the forward P/S trend, allows for an assessment of whether INVO Bioscience (INVO) is overbought amid strict R&D pipeline optimization and a limited budget for device modernization, signaling the extent to which market expectations are justified.
Who INVO Bioscience, Inc. competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio RxSight Corp|Forward Price-to-Revenue Multiple ClearPoint (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences SGHT|OBIO: Market Cap to Projected Revenue|ANIK: Forward Price-to-Revenue Multiple|InspireMD Inc. - Price to Expected Revenue Ratio|ZJYL: Forward P/S Multiple|VANI - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Xtant Medical Holdings, Inc.|Market Cap to Projected Revenue NMTC (NeuroOne)|Forward Price-to-Revenue Multiple MODD (Modular Medical)|Price-to-Projected Revenue Ratio MYO (Myomo Inc)|Price-to-Projected Revenue Ratio Envoy Medical, Inc. COCH|vivoslife.com (VVOS) - Market Cap to Future Revenue Ratio|NVNO: Forward Price-to-Revenue Multiple|Forward Price to Sales SINT (Sintx Technologies)|TNON: Forward P/S Multiple|LFWD (Lifeward Ltd.) - Price-to-Projected Revenue Ratio|AMIX (Autonomix Medical Inc.) - Forward P/S Multiple|invobioscience.com (IVF) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bone Biologics Corp (BBLG)|AXNX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Biolase, Inc. BIOL|Market Cap to Expected Sales Ratio Dynatronics Corp (DYNT)|Paragon 28 Corp - Forward P/S Multiple
